Skip to main content
Fertility9 min read

IVF Add-Ons Australia 2026: What the Evidence Says About Each

The ten IVF add-ons Australian clinics commonly offer, from ICSI to intralipid infusions, grouped by the strength of the evidence behind them, with the ICSI fees clinics publish on their own fee pages, linked and dated.

Edited by Peter Langdon, FCA

IVF clinics in Australia offer a growing menu of add-on treatments, each promising to improve your chances. Some are backed by strong evidence; others have little or none. This page groups the ten common add-ons by the strength of the evidence, and shows the ICSI fees clinics publish.

The ten add-ons at a glance

Add-onEvidenceWho it is usually considered for
ICSIStrongMale factor, poor fertilisation
PGT-AModerateAge 38 and over, recurrent miscarriage
Time-lapse monitoringModerateSeveral embryos, previous poor development
Embryo glueModerateAny transfer
Calcium ionophoreModerateRepeated fertilisation failure
Assisted hatchingWeakFrozen transfers, repeated implantation failure
ERAWeakThree or more failed transfers (unproven even then)
IMSIWeakSevere teratozoospermia only
Endometrial scratchInsufficientNo clear indication
Intralipid infusionsInsufficientNo clear indication

Add-on fees are set by each clinic and most are charged in addition to the cycle fee. TreatCompare shows the ICSI fees clinics publish below; for every other add-on, ask the clinic for the fee in writing.

What the evidence ratings mean

  • Strong: supported by several well-designed randomised controlled trials (RCTs), with a clear benefit for a defined group of patients.
  • Moderate: some RCT support. A benefit shown in specific groups, not necessarily for all patients.
  • Weak: limited or conflicting evidence from small or poorly designed studies. The benefit is uncertain.
  • Insufficient: no good-quality RCT support. Not recommended by NICE, the HFEA or RTAC. Treat it as a warning sign if a clinic presents it as standard.

These ratings draw on Cochrane reviews, NICE guidance and published RCTs.


Strong evidence

1. ICSI (intracytoplasmic sperm injection)

What it is: a single sperm is injected directly into the egg, bypassing natural fertilisation. It was developed for severe male factor infertility.

What the evidence says: strong evidence for male factor infertility (low sperm count, poor motility or abnormal morphology). RCTs confirm higher fertilisation rates than standard insemination in these cases.

For non-male-factor infertility, a 2019 Cochrane review found no benefit over conventional IVF insemination.

In short: the evidence supports it for male factor infertility, previous fertilisation failure and surgically retrieved sperm. If your partner's semen analysis is normal and you have no history of poor fertilisation, ask why ICSI is being recommended; standard insemination may work as well.

ICSI: what Australian clinics publish

38 of 97 accredited Australian clinics had a fee schedule we could read on their own website when the fee pages were last read (7 November 2026). Each fee page counts once, however many clinics it serves.

Out of pocket after Medicare

3 fee schedules on this basis: fewer than four, so no median or range is given. Listed alphabetically.

  • Care Fertility Greenslopes

    “ICSI (sperm injection on the eggs)”

    carefertility.com.au · read 2026-11-07

    A$354Out of pocket

  • Fertility North

    “ICSI Procedure Fee”

    fertilitynorth.com.au · read 2026-11-07

    A$304.70Out of pocket

  • The Fertility Centre - Liverpool (one fee page serving 3 sites)

    “ICSI”

    thefertilitycentre.com.au · read 2026-11-07

    A$300Out of pocket

A published fee is rarely the whole bill: medicines, the anaesthetist, day-surgery fees and storage are usually charged separately. Source: each clinic’s own fee page, read by TreatCompare’s AU clinic fee ingest. No figure is estimated, converted or adjusted.


Moderate evidence

2. PGT-A (preimplantation genetic testing for aneuploidy)

What it is: a small biopsy is taken from each embryo at the blastocyst stage and tested for chromosomal abnormalities. Embryos with the correct number of chromosomes are prioritised for transfer.

How it is charged: usually per embryo or per batch, plus a biopsy fee. Testing several embryos can add substantially to a cycle, so ask for the fee in writing.

What the evidence says: a 2022 Cochrane review found no clear improvement in live birth rates for unselected patients. The STAR trial showed fewer miscarriages with PGT-A but no improvement in cumulative live birth rates.

For women aged 38 and over the evidence is more favourable. Older eggs are more often aneuploid, and PGT-A can reduce the number of transfers needed. It is also reasonable for recurrent miscarriage (two or more losses) where a chromosomal cause is likely.

In short: the evidence is strongest for women 38 and over and for recurrent miscarriage. For women under 35 with no history of loss, most embryos are chromosomally normal and the case is weak. Be cautious if a clinic recommends PGT-A for all patients regardless of age or history.

3. Time-lapse embryo monitoring (EmbryoScope)

What it is: embryos are cultured in an incubator with a built-in camera that takes thousands of images as they develop. Software analyses the footage to help embryologists choose the embryo most likely to implant.

What the evidence says: the TIME trial (2020) and a 2023 Cochrane review found moderate-quality evidence that time-lapse may improve embryo selection, but the effect on live birth rates is not conclusive. Embryos are not taken out of the incubator for daily checks, which may help the culture conditions.

In short: most useful when there are several embryos and selection matters; less useful with only one or two. It is a selection tool and does not improve embryo quality.

4. Embryo glue (hyaluronic acid)

What it is: a transfer medium enriched with hyaluronic acid, used at embryo transfer, that may help implantation.

What the evidence says: a Cochrane review (Bontekoe et al., 2014) found a small but statistically significant improvement in clinical pregnancy and live birth rates, roughly one extra live birth for every 17 patients treated.

In short: a small but real benefit with minimal risk.

5. Calcium ionophore (artificial oocyte activation)

What it is: a brief chemical exposure of eggs after ICSI to trigger the activation that starts fertilisation. It addresses oocyte activation failure, where eggs do not respond normally to sperm entry.

What the evidence says: a 2020 systematic review (Sfontouris et al.) showed higher fertilisation rates in patients with previous complete fertilisation failure after ICSI. It has not been studied for routine use.

In short: evidence-based for complete fertilisation failure in a previous ICSI cycle, or very low fertilisation despite adequate sperm and egg numbers. Not for first-time patients as routine.


Weak evidence

6. Assisted hatching

What it is: a small opening is made in the embryo's outer shell (zona pellucida) with a laser, on the theory that some embryos, particularly frozen-thawed ones, have trouble hatching.

What the evidence says: a 2020 Cochrane review found very low-quality evidence of a small benefit in clinical pregnancy rates, mainly for frozen embryo transfers and after previous implantation failure. No significant benefit in unselected patients. NICE does not recommend routine use.

In short: sometimes considered for frozen transfers or after three or more failed transfers. Not for fresh transfers in first-time patients.

7. ERA (endometrial receptivity analysis)

What it is: a biopsy of the uterine lining is analysed for gene expression to choose the day of embryo transfer. The test claims to personalise the transfer window using 248 genes.

What the evidence says: the ERA-RCT (Simon et al., 2020, n=458) found no difference in live birth rates between ERA-guided and standard timing. A 2023 meta-analysis confirmed no benefit for unselected patients. Evidence is limited even for recurrent implantation failure.

In short: hard to justify on the evidence. Sometimes considered after three or more failed transfers of good-quality embryos when other causes have been ruled out. Be sceptical if a clinic recommends it routinely.

8. IMSI (high-magnification ICSI)

What it is: a refinement of ICSI in which sperm are examined at 6,000x magnification (against 400x for standard ICSI) to choose sperm with the most normal shape.

What the evidence says: a 2019 Cochrane review (13 RCTs, n=2775) found very low-quality evidence of no significant difference in live birth rates between IMSI and standard ICSI, with some marginal benefit in severe teratozoospermia. NICE does not recommend routine IMSI.

In short: only considered for severe male factor with very poor sperm morphology and repeated ICSI failure.


Insufficient evidence

9. Endometrial scratch

What it is: the uterine lining is gently scratched with a catheter in the cycle before transfer, on the theory that the healing response helps implantation. It is mildly to moderately uncomfortable.

What the evidence says: the PIP trial (Lensen et al., 2019, NEJM, n=1364), a large well-designed RCT, found no benefit in live birth rates. A 2021 Cochrane review confirmed no improvement. NICE and the HFEA do not recommend it, and many clinics have stopped offering it.

In short: the evidence is clear that it does not improve IVF outcomes. If a clinic recommends it as standard, ask it to explain the evidence.

The endometrial scratch was once widely offered across Australian IVF clinics. After the PIP trial in 2019 showed no benefit, many clinics withdrew it. If your clinic still recommends it, ask it to explain the evidence.

10. Intralipid infusions

What it is: an intravenous infusion of a soybean oil emulsion given around embryo transfer, on the theory that it calms natural killer (NK) cell activity in the uterus.

What the evidence says: no published RCTs support intralipid use in IVF. The theory that raised NK cells cause implantation failure is itself unproven, and blood NK cell levels do not reflect activity in the uterus. RTAC and RANZCOG do not recommend immune therapies for IVF.

In short: there is no good-quality evidence for it. Consider a second opinion if a clinic recommends intralipid infusions or NK cell testing as part of IVF.


Warning signs

  • Add-ons with insufficient evidence (endometrial scratch, intralipid infusions) presented as standard
  • ICSI for every patient regardless of the semen analysis
  • PGT-A for women under 35 with no history of miscarriage or failed transfers
  • Several add-ons bundled into a package without the evidence for each explained
  • Immune testing (NK cells, cytokines) followed by treatment based on the results; the tests are not validated for fertility

The RTAC Code of Practice requires clinics to give evidence-based information about add-on treatments. Ask your clinic to explain the evidence for any add-on it recommends, and to name the trials or guidelines behind it.

Where the evidence is strongest

  1. ICSI, for male factor infertility or previous fertilisation failure. Not needed for everyone.
  2. Embryo glue, a small benefit with minimal risk.
  3. Time-lapse monitoring, when there are several embryos to choose between.
  4. PGT-A, for women 38 and over or with recurrent miscarriage.

Questions to ask before saying yes

  1. Why is this add-on recommended for me, and what evidence supports it for my age and diagnosis?
  2. What is the fee, in writing, and is it per cycle, per embryo or per batch?
  3. What does the cycle cost if I decline it?
  4. Is any of it Medicare-eligible?

Published fees from accredited Australian clinics, each linked to its fee page and dated, with ANZARD success rates beside them.

Compare IVF clinics in Australia prices

Important context

IVF success rates vary by age, diagnosis, treatment type, use of donor eggs, embryo transfer approach and patient selection. TreatCompare summarises published clinic-level data for comparison and research purposes only. It is not medical advice and should not be used as the sole basis for choosing a clinic. Patients should verify current figures, treatment suitability and pricing directly with the clinic.

Source type
TreatCompare compiled research
Primary source
Provider-published information and TreatCompare research
Reporting period
2026-11-07
Last updated
2026-11-07
Figure type
Mixed sources
Use
Research and comparison only

Are you a clinic, provider or data owner?

If you believe information on this page is inaccurate, out of date, incomplete or presented without necessary context, contact us with the page URL and supporting evidence. We review correction requests promptly, but they are not automatically accepted.

Australia hub

Australia healthcare cost guides

View all Australia guides

Data funnel

Help improve Australian healthcare price data

TreatCompare gets more useful when readers send real quotes, providers verify listings, and outdated claims are corrected. Submissions are reviewed before publication.

Frequently asked questions

How much do IVF add-ons cost in Australia?

Add-on fees are set by each clinic, and most are charged in addition to the cycle fee. This page lists the ICSI figures Australian clinics print on their own fee pages, each with its basis, link and date. For any other add-on, ask the clinic for the fee in writing, and what the cycle costs if you decline it.

Which IVF add-ons have the strongest evidence?

ICSI has strong evidence for male factor infertility. PGT-A, embryo glue, time-lapse monitoring and calcium ionophore have moderate evidence for specific groups of patients. Assisted hatching, ERA and IMSI have weak evidence. Endometrial scratch and intralipid infusions have insufficient evidence.

Is PGT-A worth it?

The evidence is more favourable for women aged 38 and over and for those with recurrent miscarriage. Trials have not shown higher overall live birth rates in unselected patients. Ask your clinic why it is recommending PGT-A for you, how it is charged (per embryo or per batch), and what the evidence is for your age and history.

Should I pay for ICSI if I don't have male factor infertility?

ICSI has strong evidence for male factor infertility and previous fertilisation failure. For non-male-factor infertility, the evidence shows no benefit over standard insemination. If your partner's semen analysis is normal and you have no history of poor fertilisation, ask your clinic why ICSI is being recommended.

What is embryo glue and does it work?

Embryo glue is a transfer medium enriched with hyaluronic acid. A Cochrane review found a small improvement in clinical pregnancy and live birth rates. Ask your clinic how it is charged.

About the editor

Peter LangdonFCA

Editor, TreatCompare

Peter Langdon founded and edits TreatCompare. He is a Fellow of the Institute of Chartered Accountants in England and Wales (FCA). Every price on the site is read from a provider’s own published page and shown with that page and the date it was read; corrections are made by re-reading the provider’s page, never by typing in a figure someone sends. He does not give clinical advice.

How figures are read and checked →

Get an email when prices change

Free alerts when a new provider lists, or the lower-cost published price falls. Confirm by email; unsubscribe in one click.

Alert types

We'll send a confirmation link first. No marketing — alerts only. Unsubscribe with one click in any email.

Compare prices from verified providers

IVF & Fertility Prices Australia

Compare RTAC-accredited IVF clinics, Medicare rebates, PBS medication costs and public IVF access.

Compare

Related articles

IVF Add-On Costs Australia 2026: ICSI, PGT-A, Freezing & Storage

Compare IVF add-on costs in Australia, including ICSI, PGT-A, embryo freezing, storage, donor sperm, medication and what to ask clinics before starting treatment.

Male Factor Infertility & ICSI in Australia 2026: Tests, Treatment and Published Fees

How male factor infertility is investigated and treated in Australia, from semen analysis to ICSI, surgical sperm retrieval and donor sperm, with the ICSI and IVF fees clinics publish on their own fee pages, each linked and dated.

Free IVF in Australia 2026: Public Fertility Services by State

Public (state-funded) IVF in Australia, state by state: which public fertility services are recorded, what has and has not been published about waits and patient charges, and how a public referral works.

Do You Need Private Health Insurance for IVF? Australia 2026 Guide

What hospital cover can and cannot pay for in an Australian IVF cycle, why waiting periods matter, how it sits alongside Medicare, the Safety Net and the PBS, and where the government publishes the rules.

Bulk-Billing IVF in Australia 2026: What Is Bulk-Billed and What Is Not

How bulk billing applies to IVF in Australia, which parts of a cycle are usually still charged, and what accredited clinics publish for a cycle, each figure linked with the date it was read.

IVF Clinics Brisbane & Queensland 2026: Published Fees, Public IVF & Options

What Brisbane and Queensland IVF clinics print on their own fee pages, each figure linked with the date it was read, beside every accredited Queensland clinic's published success rates and what is known about public IVF in Queensland.

ivf add-ons australiaivf extras costpgta ivf cost australiaicsi cost australiaembryoscopeembryo glueendometrial scratchivf evidence
Compare local options
Australia IVF & Fertility Prices
Compare